DSP-5336 for Blood Cancer

This trial tests how the new drug DSP-5336 is absorbed, processed, and eliminated in individuals with blood cancers that have worsened despite standard treatments. Participants will take DSP-5336 orally, and researchers will monitor the drug's movement through their system. This trial may suit individuals whose blood cancer has not responded to other treatments and who can attend study visits for monitoring. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have received other anticancer drugs or investigational treatments within 14 days before starting the trial.

Research has shown that DSP-5336, also known as Enzomenib, is generally well-tolerated by patients. Studies have not found any serious side effects that would prevent increasing the dose, indicating that patients can handle the treatment without severe side effects interrupting it. Additionally, no major heart-related issues were reported among the patients.

Researchers are excited about DSP-5336 because it offers a new approach to treating blood cancer by potentially targeting cancer cells more precisely. Unlike conventional treatments like chemotherapy that affect both healthy and cancerous cells, DSP-5336 is designed to focus on specific pathways associated with cancer cell growth, potentially leading to fewer side effects. Additionally, the treatment involves both tablet and solution forms, which might provide more flexibility in dosing and administration compared to existing options. This unique mechanism and delivery method could offer a more targeted and convenient treatment option for patients.

Research has shown that DSP-5336 targets cancer cells in blood cancers by blocking a specific protein interaction. In some blood cancer patients, this interaction aids cancer cell survival and growth. Previous patients demonstrated promising results, with 85% responding to the treatment and 62% achieving complete remission. Additionally, DSP-5336 was well-tolerated, allowing patients to take it without severe side effects. These early findings suggest that DSP-5336 could be an effective treatment option for those unresponsive to other therapies. Participants in this trial will receive DSP-5336 as tablets and [14C]-DSP-5336 solution.¹⁶⁷⁸⁹